CONFLICT OF INTEREST STATEMENT
DSS, DFCI/Novartis
ONCOLOGY
DSS reports consulting fees from Boehringer Ingelheim and Merlin Biotech. SGD reports consulting fees from Amgen, Bayer, and Jazz and travel expenses from Loxo Oncology, Roche, and Salarius. KS receives grant funding from the DFCI/Novartis Drug Discovery Program and from KronosBio, is a member of the SAB and has stock options with Auron Therapeutics and has consulted for AstraZeneca. WBL reports prior consulting fees from Merck Sharp & Dohme Corp, ArQule Inc, and Jubilant DraxImage Inc for service on Data Safety Monitoring Boards, from Y‐mAbs Therapeutics, Inc for service on their Scientific Advisory Board, and as a consultant to Healthcasts. EC receives research support from Amgen, Astra‐Zeneca, Exelixis, GSK, Iterion, Novartis, Merck, and Mirati, and has been paid for Advisory Board participation for Bayer, Adaptimmune, and Epizyme.